Unlocking New Hope: Key Drivers Fueling the Global Friedreich’s Ataxia Drug Market
For decades, patients diagnosed with Friedreich’s Ataxia (FA) faced a grim reality: a progressive, debilitating neurodegenerative disease with absolutely no approved treatments. Patients and their families were limited to symptomatic care and physical therapy as the genetic condition relentlessly stripped away muscle coordination, mobility, and cardiac function. However, the narrative has...
0 Comments 0 Shares 56 Views 0 Reviews